DBV Technologies (NASDAQ:DBVT) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?

Posted by Stanley Muller on Sep 12th, 2026

DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $17.62 and traded as low as $12.93. DBV Technologies shares last traded at $12.97, with a volume of 125,350 shares changing hands.

Analyst Ratings Changes

DBVT has been the topic of a number of recent analyst reports. Citizens Jmp boosted their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 30th. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Weiss Ratings cut shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of DBV Technologies in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $48.50.

Read Our Latest Stock Analysis on DBVT

DBV Technologies Stock Down 8.6%

The firm has a market capitalization of $745.13 million, a PE ratio of -3.38 and a beta of -0.95. The business’s 50-day moving average price is $14.29 and its 200-day moving average price is $17.58.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds have recently modified their holdings of the stock. Truvestments Capital LLC boosted its position in DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the last quarter. Allworth Financial LP purchased a new stake in shares of DBV Technologies during the 4th quarter worth about $32,000. Royal Bank of Canada purchased a new stake in shares of DBV Technologies during the 4th quarter worth about $34,000. Persistent Asset Partners Ltd acquired a new stake in shares of DBV Technologies during the 4th quarter valued at about $115,000. Finally, Cetera Investment Advisers lifted its holdings in shares of DBV Technologies by 93.4% during the 1st quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock valued at $530,000 after buying an additional 12,243 shares during the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.